Cancer stem cells;Nowotworowe komórki macierzyste

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 66, Issue , 2012, Pages 629-636

  Wieczorek, Katarzyna ^a   Niewiarowska, Jolanta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cancer; Cancer therapy; Oncogenesis; Stem cell

Indexed keywords

EID: 84867968156     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1009706     Document Type: Review

References (43)

1. Al-Hajj M., Wicha M. S., Benito-Hernandez A., Morrison S. J., Clarke M. F.: Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA, 2003;100:3983-3988
2. Alison M. R, Islam S., Wright N. A.: Stem cells in cancer: instigators and propagators? J. Cell Sci., 2010;123:2357-2368
3. Alison M. R., Lim S. M., Nicholson L. J.: Cancer stem cells: problems for therapy? J. Pathol., 2011;223:147-161
4. Battula V. L., Evans K. W. Hollier B. G., Shi Y., Marini F. C., Ayyanan A., Wang R. Y., Brisken C., Guerra R., Andreeff M., Mani S. A.: Epithelialmesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells, 2010;28:1435-1445
5. Beier D., Hau P. Proescholdt M., Lohmeier A., Wischhusen J., Oefner P. J., Aigner L., Brawanski A., Bogdahn U., Beier C. P.: CD133+ and CD133-glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res., 2007;67:4010-4015
6. Bishop J.: Wczesny rozwój zarodkowy. W: Ssaki transgeniczne. Red: Krystyna Kruczyńska, Irena Zienkiewicz. Wydawnictwo Naukowe PWN, Warszawa 2001:45-48
7. Borovsky T., De Sousa E., Melo F., Vermeulen L., Medema J. P.: Cancer stem cell niche: the place to be. Cancer Res., 2011;71:634-639
8. Bosma G. C., Davisson M. T., Ruetsch N. R., Sweet H. O., Shultz L. D., Bosma M. J.: The mouse mutation severe combined immune deficiency (SCID) is on chromosome 16. Immunogenetics, 1989;29:54-57
9. Brestovitsky A., Sharf R., Mittelman K., Kleinberger T.: The adenovirus E4orf4 protein targets PP2A to the ACF chromatin-remodeling factor and induces cell death through regulation of SNF2h-containing complexes. Nucleic Acids Res., 2011;39:6414-6427
10. Calvi L. M, Adams G. B. Weibrecht K. W., Weber J. M., Olson D. P., Knight M. C., Martin R. P., Schipani E., Divieti P., Bringhurst F. R., Milner L. A., Kronenberg H. M., Scadden D. T.: Osteoblastic cells regulate the haematopoietic stem cell niche. Nature, 2003;425:841-846
11. Chhabra P., Brayman K. L.: Current status of immunomodulatory and cellular therapies in preclinical and clinical islet transplantation. J. Transplant., 2011;2011:1155-1179
12. Clarke M. F., Fuller M.: Stem cells and cancer: two faces of eve. Cell, 2006;124:1111-1115
13. Davidson College, Davidson, Fluorescence Activated Cell Sorting (FACS) Department of Biology, http://www.bio.davidson. edu/courses/genomics/method/ FACS.html (03.01.2012)
14. Fang D., Nguyen T. K. Leishear K., Finko R., Kulp A. N., Hotz S., Van Belle P. A., Xu X., Elder D. E., Herlyn M.: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res., 2005;65:9328-9337
15. Ghavami S., Asoodeh A., Klonisch T., Halayko A. J., Kadkhoda K., Kroczak T. J., Gibson S. B., Booy E. P., Naderi-Manesh H., Los M.: Brevinin-2R (1) semi-selectively kills cancer cells by a distinct mechanism, which involves the lysosomal-mitochondrial death pathway. J. Cell. Mol. Med., 2008;12:1005-1022
16. ®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J. Cancer Res. Clin. Oncol., 2008;134:51-57
17. Hang D., Dong H. C., Ning T., Dong B., Hou D. L., Xu W. G.: Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma. Dis. Esophagus, 2012 (w druku)
18. Jacobs J. J., Kieboom K., Marino S., De Pinho R. A., van Lohuizen M.: The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature, 1999;397:164-168
19. Jensen J. B., Parmar M.: Strengths and limitations of the neurosphere culture system. Mol. Neurobiol., 2006;34:153-161
20. Ji Q., Karnak D., Hao P., Wang R., Xu L.: No small matter: microRNAs - key regulators of cancer stem cells. Int. J. Clin. Exp. Med., 2010;3:84-87
21. Jung Y. W., Hysolli E., Kim K. Y., Tanaka Y., Park I. H.: Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies. Curr. Opin. Neurol., 2012;25:125-130
22. Kelly P. N., Dakic A., Adams J. M., Nutt S. L., Strasser A.: Tumor growth need not be driven by rare cancer stem cells. Science, 2007;317:337-345
23. Kern S. E., Shibata D.: The fuzzy math of solid tumor stem cells: a perspective. Cancer Res., 2007;67:8985-8988
24. Klonisch T., Wiechec E., Hombach-Klonisch S., Ande S. R., Wesselborg S., Schulze-Osthoff K., Los M.: Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol. Med., 2008;14:450-460
25. Lee H. J., You D. D., Choi D. W., Choi Y. S., Kim S. J., Won Y. S., Moon H. J.: Significance of CD133 as a cancer stem cell markers focusing on the tumorigenicity of pancreatic cancer cell lines. J. Korean Surg. Soc., 2011;81:263-270
26. Lenaerts L., De Clercq E., Naesens L.: Clinical features and treatment of adenovirus infections. Rev. Med. Virol., 2008;18:357-374
27. Lessard J., Sauvageau G.: Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature, 2003;423:255-260
28. Mitsuyasu R. T., Zack J. A., Macpherson J. L., Symonds G. P.: Phase I/II clinical trials using gene-modified adult hematopoietic stem cells for HIV: lessons learnt. Stem Cells Int., 2011;2011:393698 (w druku)
29. Nakanishi T., Ross D. D.: Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin. J. Cancer, 2012;31:73-99
30. Papailiou J., Bramis K. J., Gazouli M., Theodoropoulos G.: Stem cells in colon cancer. A new era in cancer theory begins. Int. J. Colorectal Dis., 2011;26:1-11
31. Quintana E., Shackleton M., Sabel M. S., Fullen D. R., Johnson T. M., Morrison S. J.: Efficient tumour formation by single human melanoma cells, Nature, 2008;456:593-598
32. Reddy N., Greer J. P., Goodman S., Kassim A., Morgan D. S., Chinratanalab W., Brandt S., Englehardt B., Oluwole O., Jagasia M. H., Savani B. N.: Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen. Exp. Hematol., 2012;40:359-366
33. Schumacher U., Nehmann N., Adam E., Mukthar D., Slotki I. N., Horny H. P., Flens M. J., Schlegelberger B., Steinemann D.: MDR-1-overexpression in HT 29 colon cancer cells grown in SCID mice. Acta Histochem., 2012;114:594-602
34. Shipitsin M., Polyak K.: The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab. Invest., 2008;88:459-463
35. Silber J., Lim D. A., Petritsch C., Persson A. I., Maunakea A. K., Yu M., Vandenberg S. R., Ginzinger D. G., James C. D., Costello J. F., Bergers G., Weiss W. A., Alvarez-Buylla A., Hodgson J. G.: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med., 2008;6:1-17
36. Spradling A., Drummond-Barbosa D., Kai T.: Stem cells find their niche. Nature, 2001;414:98-104
37. Stem Cell Information: The National Institutes of Health resource for stem cell research. http://stemcells.nih.gov/info (15.02.2012)
38. Varnat F., Duquet A., Malerba M., Zbinden M., Mas C., Gervaz P., Altaba A. R.: Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol. Med., 2009;1:338-351
39. Wang J. C., Dick J. E.: Cancer stem cells: lessons from leukemia. Trends Cell Biol., 2005;15:494-501
40. Woodward W. A., Sulman E. P.: Cancer stem cells: markers or biomarkers? Cancer Metastasis Rev., 2008;27:459-470
41. Yamashita Y. M., Jones D. L., Fuller M. T.: Orientation of asymmetric stem cell division by the APC tumor suppressor and centrosome. Science, 2003;301:1547-1550
42. Zhang K., Waxman D. J.: PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2lowLEF1low increase tumor angiogenesis. Mol. Cancer, 2010;9:319-327
43. Zhang Y., Zhang H., Wang X., Wang J., Zhang X., Zhang Q.: The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials, 2012;33:679-691